Mining the genomes of exceptional responders

Nat Rev Cancer. 2014 May;14(5):291-2. doi: 10.1038/nrc3723.

Abstract

The National Cancer Institute of the United States recently announced a major new initiative in understanding the genomes or, more broadly, the molecular phenotypes of exceptional responders. What can we expect to learn from exceptional responders? What are the potential benefits, and how do we approach studying them?

MeSH terms

  • Drug Resistance, Neoplasm
  • Genome
  • Humans
  • Molecular Targeted Therapy*
  • Neoplasms / genetics*
  • Neoplasms / therapy
  • Phenotype
  • Treatment Outcome